#USA #Boulder #Edgewise Therapeutics #EWTX #Kevin Koch

Edgewise Therapeutics to Present at J.P. Morgan Healthcare Conference

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a renowned name in the biopharmaceutical industry focusing on muscle diseases, is slated to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. This event is crucial for stakeholders in the healthcare sector, providing insights into emerging trends and innovative therapies.

Event Details

• - Date: January 13, 2026
• - Time: 8:15 AM PT (11:15 AM ET)

The company’s President and CEO, Kevin Koch, Ph.D., will lead the presentation, discussing the latest developments in Edgewise's pipeline, including first-in-class treatments aimed at severe muscle disorders and cardiac conditions. The presentation will be available for live streaming, and audiences are encouraged to log in a few minutes before to ensure connectivity.

About Edgewise Therapeutics

Founded with a commitment to transforming the lives of individuals living with debilitating conditions, Edgewise Therapeutics specializes in developing innovative treatments that target specific muscle and cardiac diseases. The company boasts considerable expertise in muscle physiology, setting the stage for a new wave of therapeutic options.

Key compounds in their pipeline include:

• - Sevasemten: This oral fast skeletal myosin inhibitor is in advanced stages of clinical testing for Becker and Duchenne muscular dystrophies.
• - EDG-7500: A cutting-edge cardiac sarcomere modulator currently undergoing Phase 2 clinical trials for treating hypertrophic cardiomyopathy.
• - EDG-15400: Another novel cardiac sarcomere modulator, this one focused on heart failure, is in Phase 1 clinical development.

The dedication of Edgewise's team is evident through their unwavering mission: to better the lives of patients and their families grappling with the challenges posed by serious muscle and cardiac diseases. For more information about their groundbreaking work, visit their website at edgewisetx.com or engage with them on LinkedIn and X.

As the J.P. Morgan Healthcare Conference approaches, there’s palpable excitement in the air for what Edgewise Therapeutics will unveil. This platform will not only showcase their pioneering research and therapies but also underscore their significant contributions to the healthcare sector. Stakeholders, investors, and interested parties alike are invited to join this engaging discourse in the hope of discovering new paths to treatment and improvements in patient health outcomes.